Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus

Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Kenji Wakayama

Abstract

Despite surgical removal of tumors with portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) patients, early recurrence tends to occur, and overall survival (OS) periods remain extremely short. The role that hepatectomy may play in long-term survival for HCC with PVTT has not been established. The operative mortality of hepatectomy for HCC with PVTT has also not been reviewed. Hence, we reviewed recent literature to assess these parameters. The OS of patients who received hepatectomy in conjunction with multidisciplinary treatment tended to be superior to that of patients who did not. Multidisciplinary treatments included the following: preoperative radiotherapy on PVTT; preoperative transarterial chemoembolization (TACE); subcutaneous administration of interferon-alpha (IFN-α) and intra-arterial infusion of 5-fluorouracil (5-FU) with infusion chemotherapy in the affected hepatic artery; cisplatin, doxorubicin and 5-FU locally administered in the portal vein; and subcutaneous injection of IFN-α, adjuvant chemotherapy (5-FU + Adriamycin) administration via the portal vein with postoperative TACE, percutaneous isolated hepatic perfusion and hepatic artery infusion and/or portal vein chemotherapy. The highest reported rate of operative mortality was 9.3%. In conclusion, hepatectomy for patients affected by HCC with PVTT is safe, has low mortality and might prolong survival in conjunction with multidisciplinary treatment.

Key words: Hepatocellular carcinoma; Portal vein tumor thrombus; Hepatectomy; Multidisciplinary treatment; Operative mortality

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
reported due to intrahepatic metastasis from PVTT. There have been reports of long-term survival after hepatectomy in patients with macroscopic PVTT. The operative mortality of major hepatectomy for HCC patients with macroscopic PVTT has not been well documented or discussed. To this end, we reviewed recent literature on the significance of hepatectomy in HCC with macroscopic PVTT with respect to the long-term survival and mortality.

Kamiyama T, Kakisaka T, Orimo T, Wakayama K. Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus. World J Hepatol 2017; 9(36): 1296-1304 Available from: URL: http://www.wjgnet.com/1948-5182/full/v9/i36/1296.htm DOI: http://dx.doi.org/10.4254/wjh.v9.i36.1296

INTRODUCTION

Hepatocellular carcinoma (HCC) is characterized by early formation of portal vein tumor thrombus (PVTT) [1]. An important prognostic factor and predictor for HCC recurrence is PVTT [2,3]. The effectiveness of transarterial chemoembolization (TACE) for HCC with PVTT remains unclear [4,5] though TACE is included in the treatment for HCC with tumor thrombus in the main portal branch [6]. However, it was suggested that hepatic arterial infusion chemotherapy might be a hopeful approach [7,8]. Because the median survival for untreated patients with PVTT is only 2.7 mo, this suggestion is especially relevant [9]. Hepatectomy for advanced HCC with removal of PVTT might also warrant consideration as an adjuvant treatment though it is usually performed as an emergency operation to avoid lethal complications [10]. Early recurrence has been reported in many cases due to intrahepatic metastasis from PVTT [11] even after tumors with PVTT in HCC patients was surgically removed. On the other hand, there have been reports of long-term survival after hepatectomy in patients with macroscopic portal invasion [12,13], but whether this treatment is optimal for patients with major PVTT remains controversial. Moreover, the operative mortality of major hepatectomy for HCC with macroscopic PVTT has not been well documented and reviewed. Therefore, we review literature published after January 2000 about the significance of hepatectomy in HCC with macroscopic PVTT with respect to long-term survival and mortality.

SURGICAL GUIDELINES FOR RESECTION IN HCC WITH PVTT

Because the cancer has already disseminated at this stage, leading to high rates of recurrence, hepatectomy for HCC with portal invasion is not recommended in the barcelona clinic liver cancer (BCLC) staging and treatment strategy. Portal invasion is associated with the development of metastatic nests, with higher incidence in tumors exhibiting microvascular invasion and/or satellite lesions [14].

According to the BCLC staging classification, sorafenib is the treatment of choice for HCC with macroscopic portal invasion (BCLC stage C). The efficacy of sorafenib in the treatment of advanced HCC was recently confirmed by the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial. In that report, the median overall survival was 7.9 mo in the placebo group compared to 10.7 mo in the sorafenib group. The benefit of sorafenib was consistent in the pre-specified stratification groups that included patients with the worst prognosis, such as those with macroscopic vascular invasion [15]. According to the BCLC staging classification, hepatectomy is contraindicated in HCC with Vp3 (tumor thrombus in the first branch of the portal vein) or Vp4 (tumor thrombus extension to the trunk or to the opposite side branch of the portal vein) and should only be performed in patients with small single tumors without signs of portal hypertension or hyperbilirubinemia. On the other hand, the proposed treatment for HCC with minimal portal invasion, such as Vp1 (tumor thrombus distal to the second branches of the portal vein) and Vp2 (tumor thrombus in the second branches of the portal vein), is hepatectomy combined with TACE in the Japan Society of Hepatology (JSH) algorithm [16]. Indeed, when hepatectomy was performed in selected patients affected by HCC with macroscopic PVTT, in combination with either postoperative arterial infusion therapy or preoperative TACE, long-term survival was achieved [17].

In the 17th Nationwide Follow-up Survey of Primary Liver Cancer report in Japan, it was stated that the survival rates of 976 hepatectomized HCC patients with Vp3 or Vp4 were 50.4%, 25.8% and 18.4% at 1, 3 and 5 years, respectively [1].

HEPATECTOMY WITH MULTIDISCIPLINARY TREATMENT FOR PVTT

The prognosis of the HCC patients with PVTT in the first branch or main trunk is very poor, with a median survival of only 2.7 mo if appropriate treatments are not employed [9]. However, in the present literature search, we identified instances of long-term survival after hepatectomy. The range of overall survival (OS) rates for patients who received hepatectomy without multidisciplinary treatment were from 14.2% to 86.5% at 1 year, 0% to 60.4% at 3 years and 0 to 33.3% at 5 years (Table 1). On the other hand, the range of the OS rates for patients who received hepatectomy with multidisciplinary treatment were from 0% to 100% at 1 year, 14.0% to 74.0% at 3 years and 21.5% to 42.0% at 5 years (Table 1). From these data, we can see that the OS rates of patients who received hepatectomy with multidisciplinary treatment tended to be superior to those of patients who did not receive multidisciplinary treatment. This favorable
Table 1  Surgical outcome of hepatectomy for hepatocellular carcinoma patients with portal vein thrombus

| Ref.          | Vp type | Patients | Child-Pugh A (%) | HBV (%) | OS, 1 yr (%) | OS, 3 yr (%) | OS, 5 yr (%) | Treatment                   |
|--------------|---------|----------|-----------------|---------|--------------|--------------|--------------|------------------------------|
| Ohkubo et al2000 | Vp234   | 47       | 91.5            | 42.6    | 53.9         | 32.2         | 23.9         | Preop TACE                  |
| Minagawa et al2001 | Vp234   | 18       | NS              | 44.4    | 82           | 42           | 42           |                              |
| Fan et al2003   | Vp34    | 19       | 78.9            | NS      | 14.2         | 0            | 0            |                              |
| Capussotti et al2004 | Vp234   | 13       | NS              | NS      | 37.6         | 14           | NS           | Postop PVI HAI              |
| Zhou et al2006  | Vp234   | 381      | NS              | NS      | 60.5         | 47           | 16           | 12                           |
| Ikai et al2006  | Vp34    | 78       | NS              | 30.8    | 45.7         | 21.7         | 10.9         |                               |
| Chen et al2006  | Vp34    | 438      | NS              | 52.1    | 16           | 18           | 11.8         |                               |
| Vp234          | 286     | 13.3     | 60.1            | 58.7    | 22.7         | 18.1         |              |                              |
| Vp34           | 152     | NS       | 62.5            | 39.5    | 5.7          | 0            |              |                              |
| Nagano et al2007 | Vp3    | 15       | NS              | 66.7    | 100          | 74           | NS           | Postop 5-FU/IFN             |
| Kamiyama et al2007 | Vp3    | 15       | NS              | 40      | 41           | 22           | NS           |                              |
| Liang et al2008 | Vp34    | 28       | 85.7            | 64.3    | 39           | 13.1         | 13.1         |                              |
| Peng et al2009  | Vp34    | 33       | 54.5            | 93.9    | 46.8         | 14.4         | NS           | Postop PIAF                 |
| Vp34           | 53      | 69.8     | 92.5            | 23.4    | 5.8          | 8            | NS           |                              |
| Ban et al2009  | Vp34    | 51       | 86.3            | NS      | 50.9         | 33.8         | 21.5         | Postop TACE                 |
| Shi et al2010   | Vp33    | 169      | 99.4            | 81.1    | 38.2         | 17.7         | NS           |                              |
| Vp4            | 78      | 97.4     | 87.2            | 24.7    | 3.6          | 6            | NS           |                              |
| Vp4            | 20      | 95       | 90              | 18.3    | 0            | 0            | NS           |                              |
| Zhou et al2011 | Vp34    | 21       | NS              | 47      | 22           | NS           |              | Adjuvant chemotherapy via portal vein |
| Vp34           | 38      | NS       | 70              | 20      | NS           |              |              |                              |
| Matono et al2012 | Vp34    | 19       | NS              | 55.2    | 62.1         | 24.1         | 17.2         |                              |
| Li et al2012    | Vp34    | 88       | 54.5            | 93.9    | 46.8         | 14.4         | NS           | Postop PIAF                 |
| Peng et al2012  | Vp34    | 68       | NS              | 92.5    | 23.4         | 5.8          | NS           |                              |
| Vp4            | 83      | NS       | 50.9            | 33.8    | 21.5         | 17.7         | NS           |                              |
| Vp4            | 33      | NS       | 21.7            | 0       | 0            | 6            | 3.6          |                              |
| Tang et al2013  | Vp234   | 186      | 91.9            | 85.5    | 40.1         | 17           | 13.6         |                              |
| Li et al2013    | Vp33    | 10       | 100             | 100     | 43           | 16           | NS           |                              |
| Vp34           | 20      | 100      | 90              | 32      | 11           | NS           |              |                              |
| Chok et al2014  | Vp34    | 71       | 95.8            | 90.1    | 45.8         | 22.7         | 11.2         |                              |
| Vp34           | 10      | 90       | 100             | 50      | 12.5         | 12.5         | NS           |                              |
| Vp34           | 34      | 85.7     | 100             | 28.6    | 14.3         | 14.3         | 7            |                              |
| Fukumoto et al2014 | Vp34   | 41       | NS              | NS      | 80.5         | 32.4         | NS           | Postop PIHP                 |
| Yamamoto et al2015 | Vp34    | 10       | NS              | NS      | NS           | NS           | 30           |                              |
| Vp34           | 20      | 100      | 100             | 50      | 12.5         | 25           | 25           |                              |
| Vp34           | 24      | 92.6     | 33.3            | 77.8    | 48.2         | 25.9         | 17.2         |                              |
| Xiao et al2015  | Vp34    | 25       | 88              | 32      | 68           | 32           | 32           |                              |
| Vp34           | 28      | NS       | NS              | 53.6    | 25           | 25           | 25           |                              |
| Vp34           | 38      | NS       | NS              | 39.5    | 15.8         | 15.8         | 15.8         |                              |
| Vp234          | 51      | 92.2     | 22              | 19.6    | NS           | NS           |              |                              |
| Vp34           | 31      | 96.8     | 19              | 53.3    | NS           | NS           |              |                              |
| Vp34           | 10      | 100      | 30              | 71.1    | NS           | NS           |              |                              |
| Zheng et al2016 | Vp234   | 96       | 78.1            | 58.3    | 86.5         | 60.4         | 33.3         |                              |
| Li et al2016    | Vp4     | 39       | 88.9            | 82.2    | 69           | NS           | NS           | Postop radiations            |
| Vp34           | 25      | 84       | 88              | 35.6    | NS           | NS           |              |                              |
| Ye et al2016    | Vp4     | 54       | NS              | 85.2    | 0            | NS           |              | Postop TACE                 |
| Vp34           | 7       | 100      | 100             | 71      | NS           |              |              | Postop TACE                 |
| Hamaoka et al2017 | Vp34   | 7        | 100             | 71      | OS           |              |              |                              |

1Tumor thrombi involving the superior mesenteric vein; 2Non-curative resection; 3Hepatectomy with caudate lobe; 4PVTT extending to or beyond the portal vein bifurcation, treated by en bloc resection followed by portal vein reconstruction; 5PVTT extending to or beyond the portal vein bifurcation, treated by thrombectomy. OS: Overall survival; HBV: Hepatitis B virus; 2P: Tumor thrombus in the second branches of the portal vein; Vp3: Tumor thrombus in the first branch of the portal vein; Vp4: Tumor thrombus extension to the trunk or the opposite-side branch of the portal vein; TACE: Transarterial chemoembolization; PVI: Portal vein infusion; HAI: Hepatic arterial infusion; PIAF: Cisplatin, doxorubicin and 5-fluorouridine (5-FU) locally administered in the portal vein with subcutaneous injection of interferon-α; PIHP: Percutaneous isolated hepatic perfusion; FAIT: FU arterial infusion and interferon therapy; HAIC: Hepatic arterial infusion chemotherapy; FP: Cisplatin+5-FU; ADM: Adriamycin; NS: Not stated.

Outcome was achieved when hepatectomy was pre- or postoperatively combined with multidisciplinary treatment. The multidisciplinary treatments included the following: Preoperative radiotherapy (RT) on PVTT in the main trunk or first branch; postoperative TACE; subcutaneous administration of interferon-alpha (IFN-α).
and intra-arterial infusion of 5-fluorouracil (5-FU)\textsuperscript{[17]}; Epi-Adriamycin/cisplatin+5-FU\textsuperscript{[18]}; cisplatin+5-FU infused in the portal vein or in the proper hepatic artery\textsuperscript{[19]}; PIAF regimen (cisplatin, doxorubicin and 5-FU locally administered in the portal vein with subcutaneous injection of IFN-\alpha)\textsuperscript{[20]}; adjuvant chemotherapy (5-FU and Adriamycin) via the portal vein\textsuperscript{[21]}; postoperative TACE\textsuperscript{[22-24]}; percutaneous isolated hepatic perfusion (PIHP)\textsuperscript{[25]}; and hepatic artery infusion and/or portal vein chemotherapy\textsuperscript{[26]}.

It was reported that the survival periods of approximately 10% of patients with tumor thrombi in the first branch and the portal trunk is more than 5 years following hepatectomy and that postoperative multidisciplinary treatments, including local and systemic adjuvant chemotherapy, are required in addition to hepatectomy to prevent intrahepatic metastasis\textsuperscript{[27]}. Fukumoto \textit{et al}\textsuperscript{[25]} described that the efficacy of PIHP for hepatectomized patients with macroscopic PVTT had a median OS of 23 mo compared with a 6.5 mo median survival for patients treated with sorafenib\textsuperscript{[15]}. However, PIHP treatment requires special equipment/expertise that is not currently available outside of Kobe University. On the other hand, Minagawa \textit{et al}\textsuperscript{[13]} reported the survival rate of 42% at 5 years for patients who underwent hepatectomy with preoperative TACE, which can be easily performed in any center, with only 9 cases exhibiting portal vein invasion in the second-order branches. It was reported that treating 15 cases of HCC with PVTT using FU arterial infusion and interferon therapy (FAIT) in addition to surgery, and 100% of the patients survived more than 1 year. In contrast, 10 patients (67%) died within 1 year without FAIT and surgery\textsuperscript{[17,30]}. Peng \textit{et al}\textsuperscript{[25]} conducted a randomized controlled trial and showed that postoperative TACE enhances the effect of liver resection combined with PVTT removal. Estimated 1-, 3- and 5-years survival rates were better in the TACE group (50.9%, 33.8%, and 21.5%, respectively) than in the control group (33.3%, 17.0%, and 8.5%, respectively).

Liang \textit{et al}\textsuperscript{[20]} reported that the efficacy of intra-portal infusion chemotherapy using the PIAF regimen. They describe their procedure for administration of chemotherapeutic agents into portal vein as an attempt to kill the residual cancer cells in the portal venous system and subsequently curtail postoperative cancer recurrence. Moreover, another randomized controlled trial reported that postoperative TACE combined with portal vein chemotherapy is beneficial for patients with HCC complicated by PVTT but that the long-term efficacy of this approach is uncertain\textsuperscript{[29]}. A combination of hepatectomy and preoperative RT has been reported to be effective for PVTT in the first branch or main trunk\textsuperscript{[12,13]}. The survival rates at 1-, 3-, and 5-year were 100%, 53.3%, and 40.0%, respectively. Therefore, one of the abovementioned perioperative treatments combined with hepatectomy for HCC with PVTT might be necessary to prolong patient survival, though which of these options are superior cannot be concluded from this review. More appropriate regimens of perioperative treatment continue to be developed. Because Ando \textit{et al}\textsuperscript{[7]} reported that hepatic arterial infusion chemotherapy (HAIC) with 5-FU and low-dose cisplatin may be a beneficial therapeutic option for patients with PVTT in the main portal trunk or in the first portal branch or in the second portal branch; this regimen may be promising as adjuvant therapy for hepatectomy in HCC with macroscopic PVTT.

As a curative treatment for HCC with PVTT, only hepatectomy might be insufficient, and multidisciplinary treatments must be required because portal invasion is associated with the development of metastatic nests.

**Significance of local treatment for PVTT**

What about targeting PVTT for local treatment? Yamanaka \textit{et al}\textsuperscript{[29]} reported that the portal pedicles should be divided before liver parenchymal dissection during segmentectomy and lobectomy to decrease the chance of dissemination of the intravasated cancer cells because the cancer cells can dislodge into the portal venous stream during hepatectomy for HCC. From this point of view, targeting the PVTT to prevent cancer cell dissemination is a desirable approach. It was reported that preoperative radiation on the PVTT caused the tumor thrombus to become completely necrotic based on pathological examination, and 5 (83.3%) of the 6 patients survived for over 2 years after treatment\textsuperscript{[12]}. Li \textit{et al}\textsuperscript{[30]} also demonstrated that better postoperative survival outcomes were provided by neoadjuvant radiotherapy before partial hepatectomy than partial hepatectomy alone for patients with HCC containing the main portal tumor thrombus. In 12 of 45 patients, the extent of PVTT after radiotherapy was significantly reduced, with the remaining 31 showing partial response (PR) and stable disease (SD) or two with progressive disease (PD)\textsuperscript{[30]}. Because the tolerance of the liver for RT is low, RT for HCC has been limited to palliative treatment\textsuperscript{[31,32]}. However, for the treatment of HCC, the effects of a high dose of local RT have been investigated\textsuperscript{[12,30]}. Minagawa \textit{et al}\textsuperscript{[13]} described that radiation hepatitis did not occur in any of their patients and no apparent late radiation-induced complications were noted in any patients. For this reason, preoperative external RT was targeting the PVTT, not the whole tumor. By their method of RT, the irradiation in the normal liver tissue was minimized and the RT dose was increased without significantly increasing toxicity. Good survival outcome of hepatectomy with preoperative TACE for HCC patients with PVTT was reported\textsuperscript{[13]}. Pathological examination detected necrosis of the PVTT in these patients. Therefore, the dissemination of HCC cells in the portal vein decrease because preoperative TACE or RT in PVTT induces necrosis. Consequently, these preoperative treatments might prevent HCC recurrence. Moreover, Hamakaka \textit{et al}\textsuperscript{[33]} reported that hepatectomy after down-staging with 3D-CRT for PVTT combined with HAIC for advanced HCC is safe and results in long-term survival outcomes. Hepatectomy for patients affected

---

**Kamiyama T \textit{et al}. Hepatectomy for HCC with macroscopic PVTT**

WJH | www.wjgnet.com

1299 December 28, 2017 | Volume 9 | Issue 36 |
by HCC with PVTT might prolong survival in conjunction with local treatment targeting PVTT: RT or TACE.

Operative mortality of hepatectomy for PVTT

Hepatectomy was indicated for living donor liver transplantation and the following liver tumors: Metastatic liver tumor, HCC, biliary malignancy. Of all the local treatments, hepatectomy for HCC had the highest local controllability and yielded a good survival outcome\(^\text{[34,35]}\). The liver functional reserve was decreased in almost all the patients with HCC because almost of patients with HCC had hepatitis B and/or hepatitis C viral infection and therefore had chronic hepatitis or cirrhosis\(^\text{[11]}\). Patients with liver cirrhosis decreased reticuloendothelial system functions, had elevated portal venous pressures, and impaired liver regeneration and coagulopathy\(^\text{[26]}\). Therefore, the mortality rates of hepatectomy in patients with liver cirrhosis was high form 8.9% to 19.6%\(^\text{[47]}\). On the other hand, recent advances in pre- and postoperative care, the decision criteria for hepatectomy and indications for hepatectomy and surgical techniques have been applied to extended hepatectomy\(^\text{[38-40]}\). Although operative mortality is not avoided even in donor hepatectomy for living donor liver transplantation, major hepatectomy become more safe by these preoperative evaluations\(^\text{[41]}\).

There were 6 papers that reported mortality within 30 d. In Ohkubo et al\(^\text{[41]}\)’s series, one patient died within 1 mo of the operation due to liver failure. In Capussotti et al\(^\text{[42]}\)’s report, two patients died within 30 d due to postoperative bleeding and liver failure. In Ikai et al\(^\text{[43]}\)’s report, patients who died within 30 d were 3, two from growth of the extrahepatic metastases and another because of pulmonary bleeding. There were 2 deaths (2.3%) recorded within 30 d after the operation due to operative mortality in Liang et al\(^\text{[44]}\)’s paper. Two patients died within 30 d of surgery due to hepatic decompensation in Tang et al\(^\text{[45]}\)’s study. Yamamoto et al\(^\text{[46]}\) described one patient dying within 30 d of the operation due to acute renal failure. Thirteen papers mentioned mortality or operative mortality without reporting times. No mortality was described in six of these papers. The other 7 papers showed the number of patients or percentage of mortality. Fan et al\(^\text{[47]}\) reported an operative mortality of 4.8%. In the control group, two patients died from operative complications in Peng et al\(^\text{[48]}\)’s study. One patient in Matono et al\(^\text{[49]}\) report died of operative morbidity. In Peng et al\(^\text{[49]}\)’s report, there was one in-hospital postoperative death due to liver failure. The overall hospital mortality was 3.4% \((n = 3)\) in Chock et al\(^\text{[47]}\)’s study. There was one in-hospital death after the operation caused by postoperative bleeding \((n = 169)\) in Shi et al\(^\text{[50]}\)’s series. Operative mortality of Group A was 0% and that of Group B was 2.6% in Chen et al\(^\text{[51]}\)’s paper. Chen et al\(^\text{[52]}\) reported a mortality of 4.5%. Ye et al\(^\text{[41]}\) reported that 5 patients died (9.3%) (liver failure: 3, serious infection: 1, and heart failure: 1). Zheng et al\(^\text{[53]}\) reported that 1 in-hospital postoperative death (1.0%) occurred in the hepatic resection group, caused by a serious postoperative infection. Mortality on postoperative day 38 and 58 was described in studies by Capussotti et al\(^\text{[42]}\) and Minagawa et al\(^\text{[54]}\), respectively (Table 2).

When an HCC with major PVTT is surgically resected, a major hepatectomy should be performed with removal of the parenchyma fed by the portal vein obstructed by the PVTT vein. This operative procedure is quite technically complicated. In Asiyambola et al\(^\text{[52]}\)’s report, the type of operative procedure (more than or equal to hemi-hepatectomy vs less than hemi-hepatectomy) was related with in-hospital mortality and, specifically, patients who underwent more than or equal to a hemi-hepatectomy had a mortality rate of 6.5% compared with 4.1% for patients who underwent less than a hemi-hepatectomy. Therefore, major hepatectomy requires a very refined technique\(^\text{[55]}\). However, the operative mortality for hepatectomy in HCC with macroscopic PVTT has not been discussed. In the present review, the highest rate of operative mortality found in the literature was 9.3%\(^\text{[24]}\). The rest were not as high compared to the rates reported by Asiyambola et al\(^\text{[52]}\), though the mortality data were represented in a variety of ways. Major hepatectomy for HCC with macroscopic PVTT has been safely performed in many cases. The estimated cause was that the majority of patients described in this review paper had a Child-Pugh A and were infected with HBV (Table 1) and thus had a good liver function reserve. Therefore, we propose that the indication for hepatectomy in HCC with major PVTT should be expanded.

LONG-TERM SURVIVAL-RELATED FACTORS: THE EXTENT OF THE TUMOR THROMBUS

What are the long-term survival-related factors? Shi et al\(^\text{[50]}\) previously classified PVTT into 4 groups by the extent of the tumor thrombus. Patients of types I and II: PVTT located in the segmental, sectoral, or right and/or left portal veins showed significantly better survival than those of types III and IV: PVTT extended to the main trunk of the portal vein or the superior mesenteric vein. Therefore, they concluded that hepatectomy with thrombectomy is justified in selected patients with HCC and PVTT located in the first, second, or lower branch of the portal vein. Zheng et al\(^\text{[51]}\) also reported that the long-term survival in patients with type I and II PVTT was remarkably improved compared with in patients with type III and IV PVTT. Moreover, Kokudo et al\(^\text{[55]}\) reported data from the nationwide survey of patients with primary liver cancer performed by the Liver Cancer Study Group of Japan, which stated that the survival benefit of liver resection was statistically significant only in patients with PVTT invading the main trunk or contralateral branch. From these data, while HCC with PVTT located in the first or second branch of the portal vein might be a relatively
good indication for hepatectomy, hepatectomy for HCC combined with PVTT in the contralateral branch or main trunk should be performed after careful consideration.

Long-term survival-related factors: Liver function
Ikai et al[27] reported that the absence of ascites, prothrombin activity, and tumor diameter are independent prognostic factors reflecting portal hypertension, liver function and tumor status, respectively. Kondo et al[54] reported negative prognostic factors of hepatectomized patients with PVTT, including age < 60 years and factors related to liver function: Total serum bilirubin > 0.8 mg/dL and serum alkaline phosphatase > 300 IU/mL. Pawlik et al[55] concluded that patients with HCC and the major vascular invasion of the main portal or hepatic vein branches derive long-term resection benefits if they have no, or minimal, underlying fibrosis. In another report, the presence of fibrosis: Moderate to severe was the individual significant predictive factor on multivariate analysis that was related with worse short-term (< 6 mo) and long-term (> 6 mo) survival. In this paper, the authors argued that this result is due to postresection hepatic decompensation and to a “field cancerization”[56] effect in the cirrhotic liver, which places these patients at a higher risk for metachronous or synchronous disease. Most of the patients described in the studies we reviewed had a Child-Pugh A and were infected HBV (Table 1). This status might be a requirement for adaptation to hepatectomy to prevent postoperative hepatic decompensation. Moreover, increased liver function reserve might lead to a better prognosis for patients with HCC complicated by PVTT after hepatectomy due to the prevention of synchronous or metachronous tumors. Of the HCC patients with macroscopic PVTT, the indication of hepatectomy should be restricted within good liver function reserve.

A limitation of this review is that most of the articles selected were published from Eastern Asian countries, and the findings may not be applicable to other regions of the world. A more comprehensive review of the global literature would be very valuable in the future.

CONCLUSION
Hepatectomy might prolong the survival of patients with HCC with PVTT when the liver function reserve is preserved, such as in Child-Pugh score A cases. Effective multidisciplinary treatments may improve the prognosis and prevent recurrence due to disseminated cancer cells in these patients. Moreover, hepatectomy may be a feasible adjunct treatment for HCC with PVTT due to the current mortality rates after hepatectomy being quite low.
ACKNOWLEDGMENTS
We thank Ms. Ayumi Hoshikawa for her help with this article.

REFERENCES

1 Ikai I, Arii S, Ozakazi M, Okita K, Omata M, Kojoj M, Takeyasu K, Nakamuna Y, Makuuchi M, Matsuyama Y, Monden M, Kudo M. Report of the 17th Nationwide follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007; 37: 676-691 [PMID: 17617112 DOI: 10.1111/j.1872-0534.2007.00119.x]

2 Arii S, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, Maetani S, Tobe T. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. Cancer 1992; 69: 913-919 [PMID: 1310434]

3 Ikai I, Arii S, Kojoj M, Ichida T, Makuuchi M, Matsuyama Y, Nakamuna Y, Okita K, Omata M, Takeyasu K, Yamaoka Y. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802 [PMID: 15305412 DOI: 10.1002/cncr.20426]

4 Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995; 165: 315-321 [PMID: 7618547 DOI: 10.224/ajr.165.2.7618547]

5 Harada T, Matsuo K, Inoue T, Tamesue S, Inoue T, Nakamura H. Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma? Ann Surg 1996; 224: 4-9 [PMID: 8678616]

6 Lee HS, Kim JS, Choi JJ, Chung JW, Park JH, Kim CY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997; 79: 2087-2094 [PMID: 9179054]

7 Ando E, Tanaka M, Yamasita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K, Sata M. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595 [PMID: 12209752 DOI: 10.1002/cncr.10694]

8 Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Dandinsuren B, Wada H, Marubushi S, Miyamoto A, Dono K, Umeshii K, Nakamori S, Monden M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 2005; 93: 557-564 [PMID: 16106266 DOI: 10.1038/sj.bjc.6602742]

9 Llovet JM, Bustamante J, Castells A, Vilarosa R, Ayuso Mdel C, Kamiyama T, Makuuchi M, Kosuge T. Surgical results for hepatocellular carcinoma and portal vein tumor thrombus: analysis of 48 cases. Cancer 1990; 88: 821-827 [PMID: 2173162]

10 Okahbo T, Yamamoto J, Sugawara Y, Shimada K, Yamasaki S, Makuuchi M, Kosuge T. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis. J Am Coll Surg 2000; 191: 657-660 [PMID: 11129815]

11 Kamiyama T, Nakashiki K, Yokoo H, Tahara M, Nakagawa T, Kamachi H, Taguchi H, Shirato H, Matsushita M, Todo S. Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma. Int J Clin Oncol 2007; 12: 363-368 [PMID: 17929118 DOI: 10.1007/s10147-007-0701-y]

12 Minagawa M, Makuuchi M, Takeyasu T, Ohtomo K. Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2001; 233: 379-384 [PMID: 1122462]

13 Tremosi S, Reig M, de Lope CR, Forner A, Bruix J. Treatment of early hepatocellular carcinoma: Towards personalized therapy. Dig Liver Dis 2010; 42 Suppl 3: S242-S248 [PMID: 20547310 DOI: 10.1016/S1590-8658(10)60512-9]

14 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-389 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

15 Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima K, Ojoj M, Kojoj M, Makuuchi M; HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364 [PMID: 21829027 DOI: 10.1159/00032777]

16 Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Ota H, Nakamura M, Wada H, Dandinsuren B, Marubushi S, Miyamoto A, Takeda Y, Dono K, Umeshii K, Nakamori S, Monden M. Hepatic resection followed by IFNa-alpha and 5-FU for advanced hepatocellular carcinoma with tumor thrombus in the major portal branch. Hepatogastroenterology 2007; 54: 172-179 [PMID: 1419255]

17 Kojima H, Hatako F, Taura K, Oso S, Yasuchika K, Ueno S. Hepatic Resection for Hepatocellular Carcinoma with Tumor Thrombus in the Major Portal Vein. Dig Surg 2015; 32: 413-420 [PMID: 26316188 DOI: 10.1159/000347375]

18 Zhou J, Tang ZY, Wu ZQ, Zhou XD, Ma ZC, Tan CJ, Shi YH, Yu Y, Qiu SJ, Fan J. Factors influencing survival in hepatocellular carcinoma patients with macroscopic portal vein tumor thrombosis after surgery, with special reference to time dependency: a single-center experience of 381 cases. Hepatogastroenterology 2006; 53: 275-280 [PMID: 16608039]

19 Liao LJ, Hu WJ, Yin XY, Zhou Q, Peng BG, Li DM, Lu MD. Adjuvant intraperitoneal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy. World J Surg 2008; 32: 627-631 [PMID: 18228094 DOI: 10.1007/s00268-007-9364-0]

20 Zhou Q, Wang Y, Zhou X, Peng B, Yang J, Liang J, Li J. Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi. Asian Pac J Cancer Prev 2011; 12: 2847-2850 [PMID: 22393952]

21 Peng BG, He Q, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Ann Surg 2009; 198: 313-318 [PMID: 19285298 DOI: 10.1016/j.amjsurg.2008.09.026]

22 Bai T, Chen J, Xie ZB, Wu FX, Wang SD, Liu JJ, Li LQ. The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus. Oncol Targets Ther 2016; 9: 3841-3848 [PMID: 27390524 DOI: 10.2147/ott.s14037]

23 Ye HY, Ye JZ, Xie ZB, Peng YC, Chen J, Ma L, Bai T, Chen JZ, Lu Z, Qin HG, Xiang BD, Li LQ. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. World J Gastroenterol 2016; 22: 3632-3643 [PMID: 27053585 DOI: 10.3748/wjg.v22.i13.3632]

24 Fukumoto T, Tominaga M, Kido M, Takebe A, Tanaka M, Karamitsu K, Matsumoto I, Ajiki T, Ku Y. Long-term outcomes and prognostic factors with reductive hepatectomy and selective percutaneous isolated hepatic perfusion for multiple bilobar hepatocellular carcinoma. Ann Surg Oncol 2014; 21: 971-978 [PMID: 24201744 DOI: 10.1245/s10434-013-3305-y]

25 Fan J, Wu ZQ, Zhou J, Qiu SJ, Shi YH, Chen RX, Tang ZY.
Hepatocellular carcinoma associated with tumor thrombosis in the portal vein: the effects of different treatments. 

Ikai I, Hatano E, Hasegawa S, Fujii H, Taura K, Uyama N, Shimazui Y. Prognostic index for patients with hepatocellular carcinoma combined with tumor thrombosis in the major portal vein. J Am Coll Surg 2006; 202: 431-438 [PMID: 16500247 DOI: 10.1016/j.jamcollsurg.2005.11.012]

Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Li HX, Qian BY, Hao XS. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis—a randomized study. World J Surg 2006; 30: 2004-2011; discussion 2012-2013 [PMID: 17058027 DOI: 10.1007/s00268-006-0271-6]

Yamanaka N, Harabuchi Y, Kataura A. The prognostic value of Ki-67 antigen in non-Hodgkin lymphoma of Waldeyer ring and the nasal cavity. Cancer 1992; 70: 2342-2349 [PMID: 1394063]

Li N, Feng S, Xue J, Wei XB, Shi J, Guo WX, Lau WY, Wu MC, Cheng SQ, Meng Y. Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy. HPB (Oxford) 2016; 18: 549-556 [PMID: 27317960 DOI: 10.1007/J.106.2014.004.03]

Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Lavigne ML, Brown MB, DuRoss DJ, Andrews JC, Ensminger WD. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992; 23: 781-788 [PMID: 1618671]

Friedman MA, Volberding PA, Cassidy MJ, Resser KJ, Wasserman TH, Phillips TL. Therapy for hepatocellular cancer with intrahepatic arterial adriamycin and 5-fluorouracil combined with whole-liver irradiation: a Northern California Oncology Group Study. Cancer Treat Rep 1979; 63: 1885-1888 [PMID: 230895]

Hamaoka M, Kobayashi T, Kuroda S, Ishako H, Okimoto S, Kimura T, Aikata H, Nagata Y, Chayahumi K, Ohdan H. Hepatocarcinoma after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study. Int J Surg 2017; 44: 223-228 [PMID: 28676383 DOI: 10.1016/j.ijsu.2017.06.082]

Arii S, Yamaoka F, Futagawa S, Inoue K, Kobayashi K, Kojo M, MAKUUCHI M, Nakamura Y, Okita K, Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatol; 2000; 32: 1224-1229 [PMID: 11093728 DOI: 10.1053/hepl.2000.20436]

Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatocellular carcinoma for intrahepatic small resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor. Ann Surg Oncol 2010; 17: 2073-2080 [PMID: 20131013 DOI: 10.1245/s10434-010-0940-4]

Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF, Zhang BX, He SQ, Zhang WG. Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 2006; 13: 940-946 [PMID: 16788755 DOI: 10.1245/sao.2006.08.007]

Chen JS, Wang Q, Chen XL, Huang XH, Liang LJ, Lei J, Huang HQ, Li DM, Cheng ZX. Clinicopathologic characteristics and surgical outcomes of hepatocellular carcinoma with portal vein tumor thrombus. J Surg Res 2012; 175: 243-250 [PMID: 21610211 DOI: 10.1016/j.jss.2011.03.072]

Zheng N, Wei X, Zhang D, Chai W, Che M, Wang J, Du B. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Medicine (Baltimore) 2016; 95: e3959 [PMID: 27367992 DOI: 10.1097/md.0000000000003959]

AsiyaAnbola B, Chang D, Glimmer AL, Nathan H, Choti MA, Schultick RD, Pawlik TM. Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg 2008; 12: 842-851 [PMID: 18266046 DOI: 10.1017/s11605-008-0494-y]

Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Uzumi N, Kadaya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N. Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. J Hepatol 2016; 65: 938-943 [PMID: 27266618 DOI: 10.1016/j.jhep.2016.05.044]

Kondo K, Chijiwa K, Kai M, Otani K, Nagaoka K, Ohuchida J, Hiyoshi M, Nagano M. Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg 2009; 13: 1078-1083 [PMID: 19296682 DOI: 10.1016/j.jgs.2009-05-0845-2]

Pawlik TM, Poon RT, Abdalla EK, Iki I, Nagorney DM, Belghiti
J, Kianmanesh R, Ng IO, Curley SA, Yamaoka Y, Lauwers GY, Vauthey JN. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137: 403-410 [PMID: 15800485 DOI: 10.1016/j.surg.2004.12.012]

Vauthey JN, Walsh GL, Vlastos G, Lauwers GY. Importance of field cancerisation in clinical oncology. Lancet Oncol 2000; 1: 15-16 [PMID: 11905680 DOI: 10.1016/S1470-2045(00)00105-4]

Ban D, Shimada K, Yamamoto Y, Nara S, Esaki M, Sakamoto Y, Kosuge T. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointest Surg 2009; 13: 1921-1928 [PMID: 19727969 DOI: 10.1007/s11605-009-0998-0]

Li H, Li B, Wei Y. Hepatocellular carcinoma patients with left portal vein tumor thrombus may benefit from left hemihepatectomy with caudate lobectomy. Hepatogastroenterology 2013; 60: 1451-1455 [PMID: 23492014 DOI: 10.5754/hge13045]

Pesi B, Ferrero A, Grazi GL, Cescon M, Russolillo N, Leo F, Boni L, Pinna AD, Capussotti L, Batignani G. Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study. Am J Surg 2015; 210: 35-44 [PMID: 25935229 DOI: 10.1016/j.amjsurg.2014.09.041]

Xiao CZ, Wei W, Guo ZX, Li SH, Zhang YF, Wang JH, Shi M, Guo RP. A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection. Oncol Lett 2015; 10: 2787-2794 [PMID: 26722243 DOI: 10.3892/ol.2015.3677]
